$1.80 -0.04 (%) Oncothyreon Inc - NASDAQ

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside

    Benzinga | Oct. 21, 2014 | 09:20AM EST
  2. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 14:34PM EST
  3. Oncothyreon Plunges On Drug Fail; Wedbush Slashes Price Target

    Benzinga | Aug. 19, 2014 | 13:40PM EST
  4. Morning Market Losers

    Benzinga | Aug. 19, 2014 | 09:54AM EST
  5. Benzinga's Top #PreMarket Losers

    Benzinga | Aug. 19, 2014 | 08:27AM EST
  6. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target

    Benzinga | Jul. 23, 2014 | 15:46PM EST
  7. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga | Jul. 23, 2014 | 14:19PM EST
  8. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  9. Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer

    Benzinga | Feb. 20, 2014 | 08:09AM EST
  10. Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

    Benzinga | Oct. 7, 2013 | 08:05AM EST
  11. Five Stocks Making Moves Under $10

    Benzinga | Oct. 2, 2013 | 09:38AM EST
  12. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 25, 2013 | 08:11AM EST
  13. US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

    Benzinga | Sep. 25, 2013 | 07:18AM EST
  14. Oncothyreon Reports Merck Serono Decision to Continue Development of Tecemotide

    Benzinga | Sep. 25, 2013 | 06:31AM EST
  15. UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline Risk

    Benzinga | Jan. 18, 2013 | 01:08AM EST
  16. UPDATE: Wedbush Securities Downgrades Oncothyreon to Neutral, Lowers PT

    Benzinga | Dec. 19, 2012 | 06:53AM EST
  17. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 19, 2012 | 03:20AM EST
  18. Morning Market Losers

    Benzinga | Dec. 19, 2012 | 03:00AM EST
  19. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 19, 2012 | 00:13AM EST
  20. Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial

    Benzinga | Dec. 18, 2012 | 23:42PM EST
  21. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 12, 2012 | 01:12AM EST
  22. UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax Outlook

    Benzinga | Aug. 24, 2012 | 05:21AM EST
  23. Oncothyreon Announces Presentation of PX-866 Clinical Data at American Association of Clinical Oncology Annual Meeting

    Benzinga | Jun. 2, 2012 | 12:21PM EST
  24. Stocks Plummet on Global Growth Worries

    MarketIntelligenceCenter | Mar. 6, 2012 | 16:22PM EST
  25. Stocks Slide as Greece Deadline Approaches

    MarketIntelligenceCenter | Mar. 6, 2012 | 10:49AM EST
  26. Oncothyreon Inc. (ONTY) Loses 37% On Wider-Than-Expected Loss

    MarketIntelligenceCenter | Mar. 6, 2012 | 10:11AM EST
  27. Oncothyreon Plunges 40% on Earnings, Date of Final Stimuvax Results

    Benzinga | Mar. 6, 2012 | 04:09AM EST
  28. Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues to Endpoint

    Benzinga | Mar. 6, 2012 | 03:10AM EST
  29. Benzinga's Top Pre-Market Losers

    Benzinga | Mar. 6, 2012 | 01:18AM EST
  30. UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

    Benzinga | Jan. 24, 2012 | 03:47AM EST
  31. HF Manager Shkreli: Betting His Career that Oncothyreon's Stimuvax Drug has a "0.000% Chance of Working"

    Benzinga | Jan. 24, 2012 | 01:45AM EST
  32. Oncothyreon Breeches HOD, Ready to Break Higher

    Benzinga | Dec. 8, 2011 | 07:21AM EST
Trading Center